Jefferies on Denali Therapeutics Inc. (DNLI): 'should be a buying opportunity for a better set up for the rest of the year'
Tweet Send to a Friend
Jefferies analyst Michael Yee reiterated a Buy rating and $45.00 price target on Denali Therapeutics Inc. (NASDAQ: DNLI)The analyst comments ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
